Introduction to the ICH considerations on nonclinical studies of oncolytic virus products in conjugation with the practice of talimogene laherparepvec

ZHANG Min; GONG Xin-jiang; SHAO Xue; YAN Li-ping; YU Bing; YE Xuan; WANG Qing-li; WANG Hai-xue

doi:10.3969/j.issn.1003-3734.2019.16.009

Home>Articles>Introduction to the ICH considerations on nonclinical studies of oncolytic virus products in conjugation with the practice of talimogene laherparepvec

DOI: 10.3969/j.issn.1003-3734.2019.16.009

Introduction to the ICH considerations on nonclinical studies of oncolytic virus products in conjugation with the practice of talimogene laherparepvec

ZHANG Min

GONG Xin-jiang

SHAO Xue

YAN Li-ping

YU Bing

YE Xuan

WANG Qing-li

WANG Hai-xue

Machine-generated Keywords：

Publication Date：2019-01-01

Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)

Pages：5( 1982-1986 )

Chinese Journal of New Drugs

PKUISTIC

ISSN：1003-3734

Year, Vol.(Issue)：2019,28(16)